**Title:** Efficacy of levodropropizine: A meta-analysis in adults and children

Dr. Alessandro 17160 Zanasi alessandro.zanasi@aosp.bo.it MD ¹, Dr. Luigi 17162 Lanata luigi.lanata@dompe.it MD ³, Dr. Giovanni 18273 Fontana giovanni.fontana@unifi.it MD ⁵, Dr. Federico 17084 Saibene federico.saibene@dompe.it MD ³, Dr. Peter 18265 Dicpinigaitis pdicpin@gmail.com MD ⁴, Dr. Rossella 17163 Balsamo rossella.balsamo@dompe.it MD ³ and Dr. Francesco 17161 De Blasio dicearchia@gmail.com MD ². ¹ Pneumology Unit, University of Bologna, S.Orsola Malpighi Hospital, Bologna, Italy ; ² Respiratory Medicine and Pulmonary Rehabilitation Section, Clinic Center, Private Hospital, Naples, Italy ; ³ Medical Department, Dompé SPA, Milan, Italy ; ⁴ Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, United States and ⁵ Department of Medicine, University of Florence, Careggi Hospital, Florence, Italy.

**Body:** Introduction: Cough is a very common symptom with deep impact on day life, often requiring an empiric treatment with antitussive agents, among which Levodropropizine is a very well tolerated peripheral drug. Objective: Our study is a meta-analysis of published studies both in adults and children, with the aim to evaluate the overall comparative efficacy of Levodropropizine. Methods: After systematic literature search, we performed a standardized meta-analysis of 7 controlled clinical studies of Levodropropizine (5 vs. central antitussives and 2 vs. placebo) assessing efficacy cough outcomes, including a total of 2633 patients. Main efficacy parameters were cough frequency, severity, and night awakenings. Results: Meta-analysis of all standardized efficacy parameters showed a highly statistically significant difference in the overall antitussive efficacy in favor of Levodropropizine vs. control treatments (p = 0.001). The heterogeneity test for the efficacy outcome was not statistically significant (p=0.0619).

Conclusions: Our meta-analysis indicates that Levodropropizine is an effective antitussive drug both in adults and children, with statistically significant better overall efficacy outcomes vs. central antitussives, in terms of reducing cough intensity, frequency and nocturnal awakenings. These results further reinforce the favorable benefit/risk profile of Levodropropizine in the management of cough.